Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Disorders of Sex Development 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 100130-nm albumin-bound paclitaxel 34Oxaliplatin 28Capecitabine 27Fluorouracil 25Albumin-Bound Paclitaxel 23Leucovorin 19Irinotecan 18Erlotinib Hydrochloride 14Cyclophosphamide 12Radiosurgery 11pembrolizumab 10Radiotherapy 10Nivolumab 10Bevacizumab 10Surgical Procedures, Operative 9avelumab 7Docetaxel 7Taxes 6Cisplatin 6ruxolitinib 5folfirinox 5Specimen Handling 5Paclitaxel 5Everolimus 5Cetuximab 5ALT-803 5trametinib 4spartalizumab 4fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Pancreatic Neoplasms × STA 9090 × Clear all
NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡